Supernus pharmaceuticals, inc. (SUPN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenues
Total revenues

392,755

408,897

302,238

215,003

147,465

92,678

12,019

1,480

803

-

Costs and expenses
Cost of goods sold

16,660

15,356

15,215

11,986

8,423

5,758

1,104

-

-

-

Research and development

69,099

89,209

49,577

42,791

29,135

19,586

17,245

23,517

30,627

35,149

Selling, general and administrative

158,425

159,888

137,905

106,010

89,063

72,612

55,590

20,132

7,928

5,080

Total costs and expenses

244,184

264,453

202,697

160,787

126,621

97,956

73,939

43,649

38,555

40,229

Operating earnings

148,571

144,444

99,541

54,216

20,844

-5,278

-61,920

-42,169

-37,752

-40,123

Other income (expense)
Interest expense

22,707

18,111

1,568

543

1,229

4,963

7,849

3,575

1,866

-

Interest income, net

21,623

13,843

2,645

-

-

-

-

-

-

-

Interest income

-

-

-

1,467

681

348

299

120

31

107

Interest expense on non-recourse liability related to sale of future royalties

-

-

-

4,548

3,541

658

-

-

-

-

Changes in fair value of derivative liabilities

-

-

-

448

193

2,809

-13,354

-710

-85

-

Loss on extinguishment of debt

-

-

-

-671

-2,338

-2,592

-9,550

-

-

-

Total other income (expense)

-1,084

-4,268

1,077

-

-

39

101

50

202

542

Total other income (expense)

-

-

-

-3,847

-6,234

-5,017

-30,353

-4,115

-1,718

649

Earnings before income taxes

147,487

140,176

100,618

50,369

14,610

-10,295

-92,273

-

-39,470

-39,474

Income tax expense

34,431

29,183

43,334

-40,852

666

630

-

-

-16,245

-399

Loss from continuing operations

-

-

-

-

-

-

-

-

-23,225

-39,075

Income from discontinued operations, net of tax

-

-

-

-

-

-

-

-

2,188

612

Gain on disposal of discontinued operations, net of tax

-

-

-

-

-

-

-

-

74,852

-

Income from discontinued operations

-

-

-

-

-

-

-

-

77,040

612

Net earnings

113,056

110,993

57,284

91,221

13,944

-10,925

-92,273

-46,284

53,815

-38,463

Cumulative dividends on Series A convertible preferred stock

-

-

-

-

-

-

-

1,143

3,430

3,430

Net income (loss) attributable to common stockholders

-

-

-

-

-

-

-

-47,427

50,385

-41,893

Basic and diluted (in shares)

-

-

-

-

-

-

-

-

1,605

-

Earnings per share
Basic (in dollars per share)

2.16

2.13

1.13

1.84

0.29

-0.26

-2.90

-2.72

-

-

Diluted (in dollars per share)

2.10

2.05

1.08

1.76

0.28

-0.26

-2.90

-2.72

-

-

Net (loss) income per common share:
Continuing operations (in dollars per share)

-

-

-

-

-

-

-

-

-16.60

-26.77

Discontinued operations (in dollars per share)

-

-

-

-

-

-

-

-

47.99

0.39

Basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

31.39

-26.38

Weighted-average shares outstanding
Basic (in shares)

52,412

51,989

50,756

49,472

47,485

42,260

31,848

17,440

-

1,587

Diluted (in shares)

53,816

54,098

53,301

51,708

51,160

42,260

31,848

17,440

-

1,587

Net product sales
Total revenues

383,400

399,871

294,097

210,078

143,526

89,571

11,552

-

-

106

Royalty revenues
Total revenues

9,355

8,276

6,367

4,686

3,038

633

-

-

-

-

Licensing revenue
Total revenues

0

750

1,774

239

901

2,474

467

1,480

803

-